{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:44:54Z","timestamp":1793385894585,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.leukres.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T17:01:14Z","timestamp":1463504474000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels"],"prefix":"10.1016","volume":"47","author":[{"given":"Jiaqiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.05.010_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.05.010_bib0010","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.05.010_bib0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.05.010_bib0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.05.010_bib0025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5581\/1516-8484.20110124","article-title":"Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia","volume":"33","author":"Bitencourt","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.leukres.2016.05.010_bib0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.leukres.2016.05.010_bib0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2016.05.010_bib0040","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.25478","article-title":"Therapeutic applications of bioactive sphingolipids in hematological malignancies","volume":"127","author":"Ekiz","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2016.05.010_bib0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4155\/fmc.13.107","article-title":"A review of ceramide analogs as potential anticancer agents","volume":"5","author":"Liu","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.leukres.2016.05.010_bib0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.leu.2405058","article-title":"Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells","volume":"22","author":"Pallasch","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.05.010_bib0055","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2012-05-431783","article-title":"B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides","volume":"120","author":"Schwamb","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.05.010_bib0060","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2012-09-455394","article-title":"Drug sensitivity and sphingolipid metabolism in CLL","volume":"120","author":"Jaeger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.05.010_bib0065","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00277-011-1212-5","article-title":"A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes","volume":"90","author":"Gencer","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2016.05.010_bib0070","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1074\/jbc.275.12.9078","article-title":"Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis","volume":"275","author":"Perry","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2016.05.010_bib0075","doi-asserted-by":"crossref","first-page":"e54525","DOI":"10.1371\/journal.pone.0054525","article-title":"Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins","volume":"8","author":"Casson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2016.05.010_bib0080","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.4161\/cc.7.21.6894","article-title":"Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK","volume":"7","author":"Nica","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2016.05.010_bib0085","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.05.010_bib0090","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.D800051-JLR200","article-title":"Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers","volume":"50","author":"Shaner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.leukres.2016.05.010_bib0095","doi-asserted-by":"crossref","first-page":"19569","DOI":"10.1073\/pnas.1115484108","article-title":"Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy","volume":"108","author":"Barcelo-Coblijn","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2016.05.010_bib0100","doi-asserted-by":"crossref","first-page":"E1913","DOI":"10.1210\/jc.2014-1340","article-title":"Dysregulated sphingolipid metabolism in endometriosis","volume":"99","author":"Lee","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.leukres.2016.05.010_bib0105","doi-asserted-by":"crossref","first-page":"25001","DOI":"10.1074\/jbc.R600010200","article-title":"When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis","volume":"281","author":"Pewzner-Jung","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2016.05.010_bib0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.onc.1201533","article-title":"BCR-ABL accelerates C2-ceramide-induced apoptosis","volume":"16","author":"Maguer-Satta","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2016.05.010_bib0115","first-page":"233","article-title":"CML and apoptosis: the ceramide pathway","volume":"40","author":"Maguer-Satta","year":"1998","journal-title":"Hematol. Cell Ther."},{"key":"10.1016\/j.leukres.2016.05.010_bib0120","doi-asserted-by":"crossref","first-page":"27855","DOI":"10.1074\/jbc.R111.254359","article-title":"Many ceramides","volume":"286","author":"Hannun","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2016.05.010_bib0125","doi-asserted-by":"crossref","first-page":"25843","DOI":"10.1074\/jbc.R200009200","article-title":"De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway","volume":"277","author":"Merrill","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2016.05.010_bib0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-3084(80)90057-2","article-title":"Analogs of ceramide that inhibit glucocerebroside synthetase in mouse-brain","volume":"26","author":"Vunnam","year":"1980","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.leukres.2016.05.010_bib0135","first-page":"5962","article-title":"Discovery and evaluation of inhibitors of human sphingosine kinase","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2016.05.010_bib0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","article-title":"Ceramides in insulin resistance and lipotoxicity","volume":"45","author":"Summers","year":"2006","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.leukres.2016.05.010_bib0145","doi-asserted-by":"crossref","first-page":"724360","DOI":"10.1155\/2013\/724360","article-title":"Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells","volume":"2013","author":"Hamad","year":"2013","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.leukres.2016.05.010_bib0150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10495-015-1109-1","article-title":"Tumor suppressive functions of ceramide: evidence and mechanisms","volume":"20","author":"Galadari","year":"2015","journal-title":"Apoptosis"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T22:54:36Z","timestamp":1600556076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":30,"alternative-id":["S0145212616301102"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.05.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}